Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Different lowing blood pressure strategies have a different clinical efficacies. Blocking the
angiotensin II type 1 receptor (Telmisartan) reduces the incidence of episodes of atrial
fibrillation in hypertensive patients with paroxysmal atrial fibrillation during 24 months
than 30% compared to Nifedipine( Adalat GITS ).
A total of 160 subjects will be included in two study groups. The Group 1 will receive
80-160mg Telmisartan per day, the remaining patients will receive Nifedipine ( Adalat GITS).
Follow-up is 24 months. The conventional 12-lead ECG recordings at twice weeks interval and
24hrs holter monitor will determine the cardiac rhythm and asymptomatic episodes of atrial
fibrillation. The target of Blood pressure after 3 months is less than 130/80mmHg.
Concomitant therapy with B-blocker and acethydrazide are allowed for the target blood
pressure during the study.
Phase:
Phase 4
Details
Lead Sponsor:
The Second Affiliated Hospital of Chongqing Medical University